

YOU ARE CORDIALLY INVITED TO


THE
Connecticut Psychiatric Society
ANNUAL MEETING AND
EDUCATIONAL SESSION

Friday, July 10, 2009

at

The Quinnipiack Club
221 Church Street • New Haven, Connecticut

An evening with keynote speaker and recipient
of the CPS Distinguished Citizen Award:



*Senator
Christopher Dodd*

Connecticut's Christopher Dodd is a senior Democratic leader in the United States Senate. A respected legislator who works in a bipartisan fashion to better peoples' lives. Dodd was an original cosponsor of the Mental Health Parity Act of 1996 and this past fall, he played a central role in the passage of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008. In his address to the membership, Senator Dodd will discuss mental health parity and the recently proposed Affordable Health Choices Act.

Gualberto Ruano, M.D., Ph.D.,
Director of Genetics Research at Hartford Hospital and
President of Genomas will join us to discuss,
"Emerging Clinical Applications of Genotype-Guided
Psychotropics for Depressive Disorders."

Registration	4:30 to 5:00 p.m.
Business Meeting	5:00 to 5:30 p.m.
Scientific Talk	5:30 to 6:30 p.m. (1 CME Credit)
Reception	6:30 to 7:00 p.m.
Dinner & Keynote Address	7:00 to 9:00 p.m. (1 CME Credit)

Attendance at the Educational Session and Keynote Address will qualify
for a maximum of 2.0 AMA PRA Category I Credits™.
Please see reverse side for learning objectives.

Learning Objectives for Senator Dodd:

- Explain how legislators approach the problem of creating a national parity law for mental illness.
- Examine how national parity experience will shape the development of national healthcare reform.
- Discuss what can be done by psychiatrists to help improve access to affordable, quality healthcare for individuals with mental illness.

Learning Objectives for Dr. Ruano:

- Discuss the clinical utility of cytochrome P450 (CYP450) genotyping in management of psychiatric drugs.
- Describe the case presentations and patient profiles where use of CYP450 genotyping can diagnose clinically intensive side effects.
- Evaluate healthcare utilization patterns in patients with CYP450 drug metabolism deficiencies.
- Appraise the features of next-generation multi-genotype arrays to diagnose and prevent the cardiometabolic and neuroendocrine side effects of antipsychotic drugs.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Connecticut State Medical Society through the Joint Sponsorship of Silver Hill Hospital and the Connecticut Psychiatric Society. Silver Hill Hospital is accredited by the Connecticut State Medical Society to provide continuing medical education for physicians. Silver Hill Hospital designates this educational activity for a maximum of 2.0 AMA PRA Category I Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Once course evaluations have been returned, CME certificates will be mailed by Silver Hill Hospital following the seminar.